| Document |
Document Title |
|
WO/2024/071540A1 |
The present invention relates to Heterorhabditis megidis NB-GJ1-2 nematode, a pest control composition including same, and a method for controlling pests using same. The nematode and composition according to the present invention shows t...
|
|
WO/2024/066377A1 |
The present invention provides a VEGF and ANG-2 bispecific antibody and use thereof. The bispecific antibody comprises: a first binding region, the first binding region comprising a single-chain antibody, and the single-chain antibody ha...
|
|
WO/2024/066115A1 |
Disclosed are a method for enhancing the anti-tumor function of a T lymphocyte and use. The method comprises the step of culturing a T lymphocyte under a physical electrical stimulation condition, wherein the T lymphocyte comprises an in...
|
|
WO/2024/067796A1 |
Provided are a non-human animal expressing a human or chimeric (e.g. humanized) IL5 and/or IL5RA protein, and a use method therefor.
|
|
WO/2024/071280A1 |
Provided, as an in-vitro evaluation system improved for evaluation of nephrotoxicity of a substance such as a compound, is a method for evaluating nephrotoxicity of a substance to be tested, the method involving a step for bringing the s...
|
|
WO/2024/068010A1 |
A first aspect of the invention relates to a nucleic acid agent capable of downregulating or inhibiting the expression or biological activity of SNX9 in a target cell, wherein the nucleic acid agent is selected from an antisense oligodeo...
|
|
WO/2024/065050A1 |
A method of preparing hair follicle-derived conditioned medium which comprises one or more bioactive factors, wherein the hair follicle is retrieved from a subject non-invasively, cultured in a culture medium for a duration sufficient fo...
|
|
WO/2024/071010A1 |
Disclosed are: a method for producing a cell population in which regulatory T cells proliferate, the method including (1) a step for culturing a cell population including pluripotent-stem-cell-derived CD4+ T cells in the presence of IL-4...
|
|
WO/2024/069186A1 |
The invention relates to a modified animal cell and a method of producing the modified animal cell having a genetic modification in one or more genes associated with genome surveillance, cell cycle control and/or cell death control. The ...
|
|
WO/2024/067354A1 |
Provided are a magnetic bead removing method and device and a storage medium. The method comprises: placing a liquid bag having a curved flow channel on a magnetic platform, a plane where the curved flow channel is arranged being located...
|
|
WO/2024/066542A1 |
Provided are a hepatolenticular degeneration cell, a preparation method therefor, and an evaluation method therefor. The hepatolenticular degeneration cell is prepared by performing in-vitro directional induced differentiation on a human...
|
|
WO/2024/073665A1 |
Provided herein is a scalable method of producing CD71+ erythroid progenitor cells for use in cell therapies, such as immunomodulatory therapies in which a T-cell response is suppressed. The method includes induction of a fetal liver/yol...
|
|
WO/2024/071671A1 |
The present invention relates to a method for the dual culture of immune cells used for immunotherapy, and more specifically, to a dual culture method in which immune cells, e.g., immune cells (PBMCs), natural killer cells, and gamma del...
|
|
WO/2024/071361A1 |
The purpose of the present invention is to provide a screening method for a coagulation inhibition activity substance or a coagulation promotion activity substance for a coagulative protein. Specifically, the present invention pertains t...
|
|
WO/2024/071382A1 |
The present invention addresses the problem of providing a pluripotent stem cell and a cell (especially, an endothelial cell) differentiated and induced from a stem cell, to which a new function is imparted. The pluripotent stem cell hav...
|
|
WO/2024/070783A1 |
The purpose of the present invention is to provide a cell culture substrate equipped with a layered myocardial cell sheet for evaluating a therapeutic effect achieved by transplantation of a normal myocardial cell sheet and a method for ...
|
|
WO/2024/066616A1 |
Provided is a high-affinity PD1 protein conjugate, which comprises an elastin-like polypeptide and a high-affinity PD1 protein connected to the elastin-like polypeptide. The conjugate significantly improves the biological half-life and b...
|
|
WO/2024/071401A1 |
The present inventors found that enhancement of Plk1 activity induces lethal chromosome dynamic abnormalities in cancer cells and inhibits the proliferation thereof. Thus, activation of Plk1 and exacerbation of chromosome instability can...
|
|
WO/2024/066165A1 |
Provided are an affinity maturation method and an anti-human PD-L1 single-domain antibody affinity maturation, relating to the field of biomedicine and antibody engineering. The antibody affinity maturation method of the present inventio...
|
|
WO/2024/067762A1 |
Provided are anti-GCC single domain antibodies (e. g., VHH domain antibodies), and chimeric antigen receptors (CARs) that bind to GCC comprising same in an extracellular antigen binding domain, a transmembrane domain, and an intracellula...
|
|
WO/2024/065883A1 |
Provided are a culture medium for nasopharyngeal carcinoma organoid culture, and a culture method and use thereof. The nasopharyngeal carcinoma organoid culture medium comprises an epidermal growth factor, a hepatocyte growth factor, an ...
|
|
WO/2024/071436A1 |
A method for producing a three-dimensional tissue body, the method comprising a step for culturing a steric structural body formed by layering cell clusters while applying stretching stimuli and/or compression stimuli thereto.
|
|
WO/2024/073010A1 |
A method of inhibiting CXCL1 in one or more natural killer (NK) cells in a subject is provided. The method involves administering one or more pharmaceutically effective doses of metformin to the subject. In another embodiment of the inve...
|
|
WO/2024/073528A1 |
Embodiments of the present disclosure concerns methods and compositions related to treatment using a CRISPR/Cas9/targeting antibody/gene targeting small guide RNA(sgRNA) fusion protein/ribonucleotide complex. The targeting of a polynucle...
|
|
WO/2024/071433A1 |
[Problem] To provide a method for manufacturing a luminal structure having an appropriate structure by three-dimensionally adjusting the unevenness inside the luminal structure. [Solution] A method for manufacturing a luminal structure, ...
|
|
WO/2024/067153A1 |
Provided are a nucleic acid for producing rAAV in an insect cell, a VP1 capsid protein mutant, and use. The nucleic acid comprises nucleotide sequences encoding adeno-associated viruses VP1, VP2, and VP3 proteins. Compared with the capsi...
|
|
WO/2024/070524A1 |
In a step for supplying a second coating solution (BB) in this cell tissue production method, when r1n (n being a natural number of 1≤n≤N) stands for the first size of each of N first coating solutions (AA), r2m (m being a natural nu...
|
|
WO/2024/068845A1 |
The invention relates to the field of genetic engineering and synthetic biology, more particularly to means and methods for facilitating genetic recombination. The application discloses novel Cre recombinase dependent recombination sites...
|
|
WO/2024/067151A1 |
Provided are an anti-respiratory syncytial virus (RSV) monoclonal antibody, a preparation method for the antibody, and related use of the antibody for immunodetection. The anti-RSV monoclonal antibody exhibits high sensitivity and high s...
|
|
WO/2024/067295A1 |
Provided is a modified red blood cell. An active agent is conjugated to an extracellular portion of a membrane protein of a red blood cell by means of a linker, wherein the linker comprises a G-containing small peptide and a maleimidoalk...
|
|
WO/2024/071375A1 |
The present invention addresses the problem of providing: a human astrocyte cell mass that is induced and differentiated from an astrocyte progenitor cell derived from a human iPS cell; a method for producing the human astrocyte cell mas...
|
|
WO/2024/067723A1 |
A respiratory syncytial virus subtype A (RSV-A) recombinant F protein, a polynucleotide, a nucleic acid construct, an expression vector, a host cell, a stabilized trimer formed by the recombinant F protein, an immunogenic composition com...
|
|
WO/2024/068728A1 |
The present invention relates to a macrophage engineered to express a Matrix Metallopeptidase and therapeutic uses thereof. Such a macrophage may be for use in treatment of an inflammatory condition comprising a fibrotic element in a sub...
|
|
WO/2024/073320A1 |
Provided herein are in vitro cultured fish compositions, methods and systems to culture cells derived from a fish source.
|
|
WO/2024/065035A1 |
Compositions and processes for fabricating sorption units or filter units containing sorbent materials, for example activated carbon or charcoal powders, are disclosed. The sorbents are embedded within a porous matrix. In some examples, ...
|
|
WO/2024/072170A1 |
Provided is a method for producing a skin organoid, the method comprising: a step for performing a first culture of a primary skin cell in a first medium with at least one support among an extracellular matrix (ECM) and polyethylene glyc...
|
|
WO/2024/070494A1 |
The present invention provides: a method for producing pancreatic endoderm cells, the method comprising a step for culturing pancreatic endoderm cells in a culture medium containing a ROCK inhibitor and KGF and/or EGF; and pancreatic end...
|
|
WO/2024/068599A1 |
The present invention refers to an in vitro or ex vivo method for reversing and/or reducing and/or inhibiting the endothelial to mesenchymal transition (EnMT) process in corneal endothelial cells, preferably in primary and/or human corne...
|
|
WO/2024/068617A1 |
The present invention concerns a modified cell comprising a transgene coding for interleukin-2 (IL-2). Said modified cell comprises a first vector comprising a sequence coding for IL-2 under the control of an inducible or constitutive pr...
|
|
WO/2024/072954A1 |
A method to oxidize pan-cancer epitopes of COL6A3 protein (peptide sequences 1. FLLDGSANV (SEQ ID NO: 1), 2. FLLDGSEGV (SEQ ID NO: 2) and 3. FLLDGSINF (SEQ ID NO: 3)) by cold atmospheric plasma treatment for developing solid tumor cancer...
|
|
WO/2024/071043A1 |
Provided is a novel production method of a hetero that enables the production of a heteromultimeric protein such as a bispecific antibody. The production method of the present disclosure, which is for producing a heteromultimeric prote...
|
|
WO/2024/064079A1 |
Cells may be grown in a bioreactor, and the cells may be activated by an activator (e.g., a soluble activator complex). Nutrient and gas exchange capabilities of a closed, automated cell expansion system may allow cells to be seeded at r...
|
|
WO/2024/061356A1 |
The present invention provides an interfering RNA targeting microtubule protein β2 (TUBB2). The interfering RNA can reduce the expression of TUBB2, thereby treating a disease related to the increase of TUBB2 expression or excessive prol...
|
|
WO/2024/063818A2 |
Methods for generating pre-oligodendrocyte progenitor cells (pre-OPCs), oligodendrocyte progenitor cells (OPCs) and pre-myelinating oligodendrocytes (preOLs) from human pluripotent stem cells are provided using chemically-defined culture...
|
|
WO/2024/062258A1 |
The present disclosure provides methods for preparing functionalised polysaccharide beads. One aspect provides a method for preparing functionalised cellulose beads. Also provided are a method for attaching cells to said functionalised p...
|
|
WO/2024/060269A1 |
The present invention relates to the field of cell model application, and particularly, to a mammal-derived cell model and use thereof in screening and/or preparing an anti-aging drug, a natural product, a healthcare food, and an additiv...
|
|
WO/2024/060424A1 |
Disclosed are a CAR-T cell secreting BiTE and use thereof, and particularly disclosed is a chimeric antigen receptor secreting BiTE. The chimeric antigen receptor comprises a leader peptide, a nanobody targeting mesothelin, an extracellu...
|
|
WO/2024/060465A1 |
The present invention provides a construction method and use of a gastruloid stem cell line. A gastruloid stem cell that can be stably passaged is established in this research, which retains the potential of stem cells to a certain exten...
|
|
WO/2024/061279A1 |
The present disclosure provides a recombinant bispecific antibody comprising i) a TSLP binding domain, and ii) an IL4R binding domain. The present disclosure provides a nucleic acid molecule encoding the recombinant bispecific antibody, ...
|
|
WO/2024/060484A1 |
Provided are a method for preparing a hemogenic endothelium cell and a method for preparing a hematopoietic stem cell, comprising inducing expression of transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG at a specific period of tim...
|
